Hepatocellular carcinoma (HCC) is the major form of liver cancer for which there is no effective therapy. Genetic modification with T-cell receptors (TCRs) specific for HCC-associated antigens, such as a-fetoprotein (AFP), can potentially redirect human T cells to specifically recognize and kill HCC tumor cells to achieve antitumor effects. In this study, using lentivector and peptide immunization, we identified a population of cluster of differentiation 8 (CD8) T cells in human leukocyte antigen (HLA)-A2 transgenic AAD mice that recognized AFP 158 epitope on human HCC cells. Adoptive transfer of the AFP 158 -specific mouse CD8 T cells eradicated HepG2 tumor xenografts as large as 2 cm in diameter in immunocompromised nonobese diabetic severe combined immunodeficient gamma knockout (NSG) mice. We then established T-cell hybridoma clones from the AFP 158 -specific mouse CD8 T cells and identified three sets of paired TCR genes out of five hybridomas. Expression of the murine TCR genes redirected primary human T cells to bind HLA-A2/AFP 158 tetramer. TCR gene-engineered human T (TCR-T) cells also specifically recognized HLA-A2
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Todd Merchen, 1, 2 Edward Kruse, 1,2 and Yukai He 1, 3 Hepatocellular carcinoma (HCC) is the major form of liver cancer for which there is no effective therapy. Genetic modification with T-cell receptors (TCRs) specific for HCC-associated antigens, such as a-fetoprotein (AFP), can potentially redirect human T cells to specifically recognize and kill HCC tumor cells to achieve antitumor effects. In this study, using lentivector and peptide immunization, we identified a population of cluster of differentiation 8 (CD8) T cells in human leukocyte antigen (HLA)-A2 transgenic AAD mice that recognized AFP 158 epitope on human HCC cells. Adoptive transfer of the AFP 158 -specific mouse CD8 T cells eradicated HepG2 tumor xenografts as large as 2 cm in diameter in immunocompromised nonobese diabetic severe combined immunodeficient gamma knockout (NSG) mice. We then established T-cell hybridoma clones from the AFP 158 -specific mouse CD8 T cells and identified three sets of paired TCR genes out of five hybridomas. Expression of the murine TCR genes redirected primary human T cells to bind HLA-A2/AFP 158 tetramer. TCR gene-engineered human T (TCR-T) cells also specifically recognized HLA-A2 1 AFP 1 HepG2 HCC tumor cells and produced effector cytokines. Importantly, the TCR-T cells could specifically kill HLA-A2 A pproximately 854,000 new cases of liver cancer, 85%-90% of which are hepatocellular carcinoma (HCC), are diagnosed annually, making it the sixth most common cancer worldwide. (1) According to the American Cancer Society, in the United States, the incidence rate of liver cancer increases the fastest among all cancers, and the number of liver cancer cases has doubled in the last decade, likely due to obesity/diabetes. (2) Liver cancer is the second leading cause of cancer death in adult men due to a lack of therapies. (3, 4) Thus, new therapeutic approaches for liver cancer are urgently needed. Activation of the host immune system has been shown to generate significant antitumor effects. (5, 6) For example, checkpoint blockade unleashes a patient's immune responses, generating therapeutic effects in a variety of cancers, (7) including HCC. (8) While that is promising, the antitumor efficacy of programmed death 1 (PD-1) blockade depends on the preexistence of tumorspecific infiltrating T cells that are not always available. (9) Additionally, unleashing nonspecific immunity by checkpoint blockade may cause autoimmune destruction. On the other hand, immunotherapy targeting tumor-specific or tumor-associated antigens is less likely to cause autoimmune diseases.
Human a-fetoprotein (AFP) is reexpressed in approximately 70%-80% of HCC tumors, (10, 11) serving as a biomarker for diagnosis and a potential target for immunotherapy. Butterfield et al. identified four human leukocyte antigen (HLA)-A2-restricted AFP epitopes and developed peptide-based and vectorbased vaccines. (12, 13) Though modest AFP-specific cluster of differentiation 8 (CD8) responses were detected, no antitumor effect was observed in HCC patients. (14) A more effective, specific immunotherapy is adoptive transfer of tumor-specific autologous T cells. (15, 16) Unfortunately, most tumor-specific T cells are of low affinity or cannot be expanded from patients. One way to obtain high-affinity antigen-specific T cells is to genetically modify a patient's T cells with tumor-specific T-cell receptors (TCRs). (17) (18) (19) Identification of tumor antigen-specific TCRs is the first critical step in T-cell engineering and adoptive cell therapy. Recently, Sun et al. cloned an AFP 158 epitope-specific TCR from human T cells. (20) Not surprisingly, this AFP 158 -specific TCR has little antitumor effect because of its low affinity. In a meeting abstract, Gerry et al. (21) reported that mutations in the complementarity-determining region (CDR) of an AFP 158 -specific human TCR (22) could increase its affinity and showed that human T cells transduced with the affinity-enhanced TCR (TCR-T cells) could better recognize HCC tumor cells. The antitumor efficacy of this AFP-specific TCR-T cell is being tested in a recent approved clinical trial. However, reports of severe on-target and off-target toxicity of melanomaassociated antigen A3 (MAGE-A3) TCR-T (23, 24) suggest that more TCRs are needed in order to select the optimal TCRs that can provide human T cells the tumor-killing activity without toxicity to normal cells. Thus, there is a strong demand for more effective and safe AFP-specific TCRs for HCC immunotherapy.
In this study, we developed an effective strategy to identify TCRs for HLA-A2 presented AFP 158 epitope. We first established an immunization approach of lentivector (lv)-prime and peptide-boost to elicit high-level CD8 responses in HLA-A2 transgenic AAD mice. A large number of AFP 158 -specific CD8 T cells generated in mice without repeated in vitro restimulation should keep their TCR diversity and enabled us to study their antitumor effects prior to TCR identification. We found that the AFP 158 -specifc mouse CD8 T cells recognized and killed human HCC tumor cells in vitro and eradicated large human HepG2 tumors in nonobese diabetic severe combined immunodeficient gamma knockout (NSG) mice. We then identified three pairs of TCRs out of five hybridomas. Transduction of human T cells with the mouse TCR genes redirected them to specifically recognize and kill HepG2 tumor cells without toxicity to normal hepatocytes in vitro. Adoptive transfer of the human TCR-T cells eradicated HepG2 tumor in NSG mice.
In conclusion, we have identified AFP 158 -specific TCRs with a great potential to redirect a patient's autologous T cells for HCC treatment.
Materials and Methods

MICE
HLA-A2 transgenic AAD mice (female 7-8 weeks) and immunocompromised NSG mice (female 7-10 weeks) were obtained from Jackson Laboratory. The AAD mice express a chimeric major histocompatibility complex I (MHCI) of human HLA-A0201 a1-a2 domain and mouse H-2D d a3 domain (binding mouse CD8). (25) 
TUMORS
Five million HepG2 cells were inoculated into the flank of NSG mice. Tumor growth was monitored by measuring the length, width, and height of the tumors. Tumor volume was calculated as 1/2(length 3 width 3 height).
RECOMBINANT lv AND IMMUNIZATION
The AFP and influenza virus PR8 M1 genes were cloned into lv to generate AFP-lv and Flu-M-lv. Lvs were prepared and titrated. (26, 27) Mice were subcutaneously immunized with AFP-lv (28) or Flu-M-lv and boosted 12-15 days later with AFP 158 (FMNKFIYEI) or M1 58 (GILGFVFTL) peptide. (29) TETRAMER STAINING Splenocytes were stained with indicated surface markers, Tet 158 tetramers (NIH Tetramer Core Facility), and/or the anti-Vb antibody panel (BD Biosciences). Tetramer staining was conducted before antiVb antibody staining.
T-CELL HYBRIDOMAS
T-cell hybridomas were created by fusing the sorted mouse CD8
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Tet 158
1 cells with BW-Lyt2.4 cells that lacked the TCR a and b chains and selected in HAT medium as described. (30) Single-hybridoma clones were obtained by serial dilution.
IDENTIFICATION OF PAIRED TCRa AND b CHAINS
The technique 5 0 rapid amplification of complementary DNA ends (31) was conducted to amplify the TCR a and b genes. Briefly, total RNA was isolated from hybridomas, and complementary DNA was made with an oligo dT primer. PolyC was added to the 5 0 end of complementary DNA by terminal transferase. PCR was conducted using the 5 0 pGI primer (CACCGG-GIIGGGIIGGGIIGG) and 3 0 primers corresponding to the constant (C) region of the a (GGCATCA-CAGGGAACG) or b (CCAGAAGGTAGCAGA-GACCC) chain. Based on the obtained sequence of a and b variable (V) regions, specific primers corresponding to the V region of the a (ATGAAATCC TTTAGTATTTCCC) or b (ATGGGCTCCAGG CTCTTTCTG) chain were used with an internal primer of the a C region (GCACATTGATTTGG-GAGTC) or the b C region (GGGTAGCCTTTT GTTTGTTTG) to amplify the V region. Nucleotide sequences of the TCR a and b chains were obtained.
TCR GENES AND RECOMBINANT lv
TCR a and b genes were designed from the aboveidentified V-D-J region. The C region of the TCRa chain and the C2 region of the TCRb chain were used to create the full-length TCRs. A P2A sequence (32) was inserted between the a and b chains. The entire TCR genes were codon-optimized, synthesized, and cloned into lv.
TRANSDUCTION OF HUMAN T CELLS
Human T cells were isolated from the buffy coat of healthy donors by negative selection and activated by the CD3/CD28 tetrameric antibody complex (Stemcell Technologies) for 2 days before they were transduced with lv. The CD3/CD28 antibody complex was rinsed away 2 days after stimulation. Twenty units of interleukin-2 (IL-2) was in the culture through the process.
3-(4,5-DIMETHYLTHIAZOL-2-YL)-2,5-DIPHENYLTETRAZOLIUM BROMIDE ASSAY
To measure the live HepG2 cells after overnight coculture with mouse splenocytes, a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was performed as described. (33) INTRACELLULAR STAINING AND ENZYME-LINKED IMMUNOSORBENT ASSAY Peripheral blood cells or splenocytes were restimulated with indicated peptides in the presence of GolgiStop (Biolegend) for 4 hours and intracellularly stained for interferon-gamma (IFNc) or IL-2 as described. (34) Enzyme-linked immunosorbent assay (ELISA) of IFNc and IL-2 was conducted per the instructions (Biolegend).
LACTATE DEHYDROGENASE ASSAY AND PROPIDIUM IODIDE STAINING
TCR-T cells were cocultured with HepG2 tumor cells (5 3 10 4 ) at indicated effector to target cell (E/T) ratios overnight. The cytotoxicity of TCR-T cells was determined by measuring the lactate dehydrogenase (LDH) activity in the coculture media as instructed (Promega). The HepG2 cells after coculture with TCR-T were then stained with propidium iodide (PI; BD Biosciences).
ADOPTIVE CELL TRANSFER
The indicated numbers of splenocytes, T-cell populations, or human TCR-T cells were transferred into NSG mice bearing human HepG2 tumors. TCR-T cells in mouse blood were monitored by immunological staining.
STATISTICAL ANALYSIS
Statistical analyses were performed using t test or analysis of variance (GraphPad Inc.).
Results
IMMUNIZATION OF AAD MICE ELICITS A HIGH LEVEL OF AFP 158 -SPECIFIC CD8 T CELLS THAT RECOGNIZE AND KILL HUMAN HepG2 CELLS
To induce CD8 T cells that can recognize the HLA-A2/AFP 158 complex, we immunized AAD mice with AFP-lv or AFP peptide. We found that AFP-lv immunization induced a modest level of AFP 158 epitope-specific CD8 responses, whereas peptide did not (Fig. 1A) . However, AFP 158 peptide significantly boosted the lv-primed CD8 responses ( HepG2 tumor cells. In addition, after coculture with the immunized splenocytes, the AFP 1 HepG2 cells were killed in a dose-dependent manner (Fig. 1C,D) . Together, the data suggest that immunization of AAD mice with lv-prime and peptide-boost elicits a high level of AFP 158 -specific CD8 T cells that recognize and kill HepG2 tumor cells.
ADOPTIVE TRANSFER OF IMMUNIZED AAD MOUSE SPLENOCYTES PREVENTS AND ERADICATES LARGE HepG2 TUMORS
In this adoptive transfer experiment, we found that splenocytes from AFP-immunized AAD mice completely prevented HepG2 tumor challenge in NSG mice ( Fig. 2A,B) . Strikingly, adoptive transfer of immunized AAD splenocytes was able to eradicate HepG2 xenografts as large as 2 cm in diameter (Fig. 2C) .
ADOPTIVE TRANSFER OF AFP 158 -SPECIFIC CD8 T CELLS ERADICATES HepG2 TUMORS
To further define the immune cells with an antitumor effect, we isolated CD8 T cells from AFPimmunized AAD mice (Fig. 3A) . CD8 T cells from AAD mice immunized with influenza virus M1 antigen were used as the control. We found that adoptive transfer of CD8 T cells from AFP-immunized mice eradicated HepG2 tumors (Fig. 3B) . In contrast, the HepG2 tumors continued growing in the NSG mice that received CD8 T cells from M1 antigenimmunized mice. Next, we isolated AFP 158 -specific CD8 T cells by tetramer sorting (Fig. 3C) . After adoptive transfer, only the Tet 158 1 CD8 T cells could eradicate HepG2 tumors in NSG mice (Fig. 3D) . Together, the in vitro and in vivo data verify that AAD mouse CD8 T cells specific for the HLA-A2/ AFP 158 complex can recognize and kill human HCC tumor cells. 
T-CELL HYBRIDOMAS CREATED FROM Tet 158
1
CD8 T CELLS BIND TO Tet 158 TETRAMER
To identify paired TCR a and b chains, we created T-cell hybridomas. Prior to generating T-cell hybridomas, the TCR Vb chains of Tet158 1 cells were characterized. Approximately 90% of the Tet 158 1 CD8 T cells could be stained by anti-Vb8.3 antibody ( Supporting Fig. S1) ; the other 10% of Tet 158 1 CD8 T cells were stained with antibodies against Vb2, Vb4, Vb5.1/5.2, Vb6, or Vb11. We obtained 39 T-cell hybridomas that were stained by Tet 158 tetramers (Fig.   4A ). Twenty-five of them could be stained by antiVb8.3 antibody (data not shown). Further experiments showed that five of the anti-Vb8.3
1 T-cell hybridomas responded to AFP 1 HepG2 tumor cells and produced IL-2 (Fig. 4B ).
PAIRED TCR a AND b CHAINS WERE IDENTIFIED FROM HYBRIDOMAS
The paired TCR a and b chains from the five IL2-producing hybridomas after coculture with HepG2 cells were amplified and sequenced. The result is summarized in Fig. 4C . Out of these five hybridomas, three unique sets of TCR genes were identified. The amino acid (AA) sequences of the TCR a and b chains were compared to the National Center for Biotechnology Information and the International Immunogenetics Information System databanks. The data show that all three TCRa chains have the same variable region (TRAV7D-2) and that the TCRb chains share the same TRBV13-1 variable region (corresponding to Vb8.3 antibody staining). Detailed analysis revealed that TCR1 and TCR2 are similar. The b chains of TCR1 and TCR2 were identical; the a chains of TCR1 and TCR2 had two-AA differences in the V-J junction. On the other hand, TCR3 is more divergent from TCR1 and TCR2. Although the b chain of TCR3 differs from that of TCR1 and TCR2 by one AA, the a chain J region of TCR3 is encoded by a different gene, which makes the TCR3 a chain 10 AA different from the TCR1 and TCR2 a chains in the CDR3 region. 
EXPRESSION OF TCR a AND b CHAINS IN HUMAN T CELLS FORMS FUNCTIONAL TCRs
To study whether the mouse TCR genes could engineer human T cells to create TCR-T cells that recognize the HLA-A2/AFP 158 complex, we synthesized the TCR1, TCR2, and TCR3 genes and cloned them into lv (Fig. 5A) . First, transduction of Jurkat cells with TCR-lv showed that expression of the TCR genes enabled them to bind Tet 158 tetramer. The mean fluorescence intensity (MFI) of Tet 158 staining on the TCR3-transduced cells was higher (Fig. 5B) . Then, we studied whether the TCR genes could redirect primary human T cells to recognize the HLA-A2/ AFP 158 complex. Primary T cells were isolated from healthy donor buffy coat and transduced by lv after CD3/CD28 activation (Fig. 5C ). Using green fluorescent protein (GFP) as a reporter, we found that approximately 60% of human T cells were transduced by GFP-lv at a multiplicity of infection of 10 (Supporting Fig. S2 ). Transduction of human T cells with TCR genes enabled 20%-30% of them to bind Tet 158 tetramer (Fig. 5D) . Although different donors' T cells were transduced with different efficacies, there was no significant variation among the TCRs. Again, the MFI of Tet 158 staining was consistently higher on the TCR3-T cells, indicating that TCR3 may have a higher affinity for the HLA-A2/AFP 158 complex. Both CD8 and CD4 TCR-T cells could bind the Tet 158 tetramer. However, the MFI of Tet 158 staining on CD8 TCR-T cells was higher (Fig. 5E ), suggesting that CD8 enhanced binding of the TCR to the HLA-A2/AFP 158 . When the TCR-transduced T cells were stained with anti-Vb8.3 or the Tet 158 tetramer separately, the percent of Tet 158 1 cells was nearly identical to the percent of anti-Vb8.3 1 cells (Supporting Fig.  S3 ), suggesting that there was no mispairing with endogenous human TCRs. (Fig. 6A) . Intracellular staining showed that the IFNc was mainly produced in CD8 TCR-T cells (Fig. 6B) . However, both CD4 (Fig. 6C) and CD8 (Fig. 6B ) TCR-T cells were able to produce IL-2. There was no significant difference among the three TCRs. Furthermore, the TCR-T, especially the CD8 TCR-T, cells underwent significant proliferation after coculture with HepG2 cells (Fig. 6D) .
HUMAN TCR-T CELLS CAN
HUMAN TCR-T CELLS HAVE POTENT AND SPECIFIC CYTOTOXICITY AGAINST HepG2 TUMOR CELLS
In this study, we investigated the cytotoxicity of TCR-T cells. Using an LDH assay, we found that TCR-T cells killed 80% of HepG2 tumor cells in 24 hours at a low E/T ratio, whereas they did not generate a significant cytotoxic effect on the AFP -or HLA-A2 -tumor cells (Fig. 7A) . The cytotoxicity against HepG2 cells was dose-dependent ( Fig. 7B) . At an E/T ratio of 0.5 (the real E/T ratio was 0.15 because only 30% of T cells were Tet 158 1 cells), 50% of HepG2 cells were killed, suggesting that TCR-T cells could have multiple killing of HepG2 cells. Using purified T subsets, we showed that the tumor killing activity was mainly from the CD8 TCR-T cells (Fig.  7C-E) . However, CD4 TCR-T cells also had a lower level of cytotoxicity, resulting in 15% of specific killing at a ratio of 1.5/1 (Fig. 7E) . The CD8 TCR-T cells encircled the HepG2 cells to form clusters (Fig. 7D) . On the other hand, the CD4 TCR-T and mocktransduced T cells did not form obvious clusters. The PI staining revealed that the cluster contained mainly dead cells (Fig. 7F) . PI staining also showed that, whereas CD8 TCR-T cells may have the dominant cytotoxicity, CD4 TCR-T cells also had a lower activity of killing HepG2 tumor cells, in concordance with the LDH assay. Mock-transduced human T cells did not induce death of HepG2 tumor cells in all assays. The specificity of TCR-T cells was further studied in vitro by examining whether they could recognize and kill normal hepatocytes. The data showed that all three TCR-T cell types did not recognize and kill normal hepatocytes (Supporting Fig. S5 ).
ADOPTIVE TRANSFER OF TCR-T CELLS GENERATES ANTITUMOR EFFECT IN NSG MICE
To evaluate the TCR-T cells' in vivo antitumor effect, NSG mice bearing HepG2 tumors were adoptively transferred with human TCR-T cells (Fig.  8A) . We found that adoptive transfer of TCR-T cells inhibited HepG2 tumor outgrowth in NSG mice (Fig.  8B) . One of the TCR-T cell-treated mice developed a tumor, but the tumor was eradicated by 3 weeks posttransfer (Fig. 8C,D) . In contrast, HepG2 tumors continued growth after transfer of the mock-transduced T cells. Both the mock-T and TCR-T cells survived approximately 3-4 weeks in the absence of human IL-2 administration (Fig. 8E) . There was, however, a significant increase in Tet 158 1 cells among the TCR-T cells on day 8 posttransfer (Fig. 8F) . To examine the in vivo antitumor effect of different TCR-T subsets, we separated CD4 and CD8 TCR-T cells after transduction and transferred them separately into HepG2 tumor-bearing NSG mice. We found that adoptive transfer of either T-cell subset could generate an antitumor effect (Supporting Fig. S6A) . Also, the kinetics showed that the percent of Tet 1 cells increased after adoptive transfer into HepG2 tumor-bearing mice (Supporting Fig. S6B ), consistent with data in Fig. 8F , suggesting that there may be an antigen-induced TCR-T expansion. Phenotype staining showed that nearly half of the total and CD8 TCR-T cells and a third of CD4 TCR-T cells in NSG mice were of naive-like phenotype (CD45RA 
Discussion
In this study, we established an effective immunization strategy to obtain a large number of AFP 158 -specific (Tet 158 ) mouse CD8 T cells that specifically recognized and killed human HepG2 tumor cells in vitro and eradicated large HepG2 tumor xenografts in NSG mice. Subsequently, we established T-cell hybridomas from the Tet 158 CD8 T cells, which allowed us to identify three pairs of TCR a and b chains that bound the HLA-A2/AFP 158 complex. The TCR genes enabled human CD8 T cells to specifically recognize and kill HepG2 tumor cells in vitro. Furthermore, adoptive transfer of the TCR-T cells could eradicate HepG2 tumors in NSG mice.
TCR-T cells have been studied in a number of clinical trials, (35) which include TCRs specific for tumorassociated antigens of p53, (36) carcinoembryonic antigen, (37) MAGE3, (23, 24) GP100, (16) MART1, (38) and NY-ESO. (39) Most of the TCR genes, including the recently reported AFP 158 -specific TCRs, (20, 22) were isolated from T-cell clones established by repeated in vitro antigen stimulation, which might significantly reduce TCR diversity. For example, after 4 weeks of in vitro stimulation, only one TCR sequence was found in 19 of the GPC3 367 -specific T-cell clones. (40) Compared to this conventional approach of repeated in vitro antigen stimulation, we established an effective in vivo immunization strategy in the HLA-A2 mice using one lv-prime and one peptide-boost. This approach generates a large number of AFP 158 -specific CD8 T cells, which allows us to study their specific killing of tumor cells in vitro and to validate their antitumor function in vivo. Importantly, the large number of T cells enabled us to create T-cell hybridomas without repeated restimulation, which should maintain the diversity of the TCR repertoire. Not surprisingly, we were able to identify three unique sets of TCRs out of five T-cell hybridomas. There are an additional 34 Tet 158 1 T-cell hybridomas that can also be the resource for finding an optimal TCR of strong antitumor activity without on-target and off-target toxicity.
TCRs specific for human tumor antigens can be identified from human T cells or HLA-A2 transgenic mice. Human TCR is inherently of low affinity because of negative selection and may require affinity enhancement to achieve effective recognition of tumor antigens. (21, 41) On the other hand, murine TCRs can recognize human antigenic epitopes with high affinity. However, high-affinity TCRs have a higher chance of cross-recognizing off-target antigens, (42) resulting in toxicity. It has been demonstrated that the TCRs derived from conventional HLA-A2 mice had a higher affinity than the TCRs derived from the HLA-A2/K b mice with chimeric MHCI. (43) Thus, in our study, we intentionally used AAD mice, in which the MHCI is a chimeric molecule consisting of the a1-a2 domain of HLA-A2 and the a3 domain of mouse H-2D d . This chimeric MHCI molecule makes the mice more responsive to antigen immunization because mouse CD8 molecules bind the a3 domain of MHC to help T cells engage with antigen-presenting cells. At the same time, the provision of CD8 assistance should increase the likelihood of generating CD8 T cells with optimal TCR affinity (not very high affinity). Additionally, the use of murine TCRs minimizes mispairing with endogenous human TCRs, (44) reducing the chance of generating off-target toxicity. We found that the percent of TCR Vb chain 1 cells is very close to the percent of Tet 1 cells, suggesting that, indeed, there is no TCR mispairing in the transduced human T cells. However, murine TCR was found to be immunogenic in a portion of patients, though the immunogenicity did not correlate to a lower antitumor effect (36) ; thus, humanization may be needed for repeated use of TCR-T cells in patients.
The three sets of AFP 158 -specific murine TCRs were also able to render CD4 T cells capable of binding the Tet 158 tetramer. The production of IL-2 by CD4 TCR-T cells in response to HepG2 tumor cells may provide the cytokine necessary for maintaining Tcell proliferation in vivo. Additionally, CD4 TCR-T cells demonstrated low cytotoxicity against HepG2 tumor cells. In fact, adoptive transfer of sufficient CD4 TCR-T cells resulted in potent antitumor effects in NSG mice. Thus, although CD8 TCR-T cells may be the major player in the killing of AFP 1 tumor cells, CD4 TCR-T cells can also generate an antitumor effect.
Another factor that affects the TCR-T antitumor efficacy is the T cells themselves. One recent study found the CD26 hi T cells were more persistent after transfer and generated a potent antitumor effect, (45) which may be the better T-cell subset for TCR engineering. On the other hand, we found that stemlike memory T cells with naive-like phenotype generated a better antigen response in vivo. (46) In the current study, we found that a significant portion of TCR-T cells were of naive-like phenotype (CD45RA 1 CD62L 1 ) in NSG mice. Whether the CD45RA 1 CD62L 1 cells are more responsive to antigen and thus generate a better antitumor effect on TCR-T cells remains to be studied.
Adoptive transfer of TCR-T cells has generated remarkable antitumor effects in multiple myeloma (47) and in synovial cell sarcomas and melanoma, (48) suggesting that TCR-engineered T cells have a great potential to control solid tumors. However, the liver is equipped with a number of immunosuppression mechanisms, (49) posing a significant barrier to the success of HCC immunotherapy. But a recent report showed that some immune suppression in the liver could be overcome by checkpoint blockade, (50) opening the possibility that the combination of TCR-T cells with PD-1 blockade may enhance the antitumor effect in an immunosuppressive microenvironment. Though our initial study showed no significant toxicity on normal primary hepatocytes by our AFP-specific TCR-T cells, in light of the severe toxicity recently observed after adoptive transfer of MAGE-A3-specific TCR-T cells, (23, 24, 51) the on-target and off-target toxicity of our TCR-T cells should be extensively examined in preclinical models (52) before conducting clinical trials to test their antitumor effect. The multiple TCRs identified in this study provide an increased arsenal for T-cell engineering and HCC immunotherapy. And the diverse TCR repertoire pool gives us the resources and a higher chance of finding the optimal TCR for a strong antitumor effect without causing severe ontarget and off-target toxicity. Considering that the Food and Drug Administration has approved two chimeric antigen receptor gene-modified T cells for immunotherapy of hematological tumors, the AFPspecific TCR genes identified in this study, if proved to be safe, should have a great potential of being used to modify patients' autologous T cells for adoptive cell therapy of HCC.
